NCT02298933View on ClinicalTrials.gov

Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 21, 2014

Primary Completion Date

August 8, 2017

Study Completion Date

August 8, 2017

Conditions
ThrombocytopeniaAlloimmune Platelet Refractoriness
Interventions
DRUG

Eculizumab

300 mg single-use vials

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT02298933 - Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia | Biotech Hunter | Biotech Hunter